重大事件
即時報告
8-K
2026-05-27
BridgeBio Pharma提交8-K公告重大業務進展 附新聞稿詳述事件細節
AI 繁中摘要
BridgeBio Pharma, Inc.（納斯達克代碼：BBIO）於2026年5月27日向美國證監會提交了一份8-K表格，報告一項其他事件（Item 8.01），同時提供相關財務報表及展品（Item 9.01）📄。該公司隨附了一份新聞稿作為附件99.1，詳細說明了事件的具體內容。雖然8-K正文未直接披露細節，但管理層通常透過此類申報公告重大業務進展，例如臨床試驗結果、監監管里程碑、合作協議或融資活動。投資者應仔細查閱附件99.1以評估潛在影響。BridgeBio是一家專注於遺傳性疾病創新藥物的生物製藥公司，總部位於加州帕羅奧圖。
展開英文正文
EDGAR Filing Documents for 0001140361-26-022979 SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001140361-26-022979 Filing Date 2026-05-27 Accepted 2026-05-27 16:01:34 Documents 12 Period of Report 2026-05-27 Items Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits Interactive Data Document Format Files Seq Description Document Type Size 1 8-K ef20074977_8k.htm iXBRL 8-K 29471 2 EXHIBIT 99.1 ef20074977_ex99-1.htm EX-99.1 20085 Complete submission text file 0001140361-26-022979.txt 184406 Data Files Seq Description Document Type Size 3 XBRL TAXONOMY EXTENSION SCHEMA bbio-20260527.xsd EX-101.SCH 3868 4 XBRL TAXONOMY EXTENSION LABEL LINKBASE bbio-20260527_lab.xml EX-101.LAB 21966 5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bbio-20260527_pre.xml EX-101.PRE 16046 15 EXTRACTED XBRL INSTANCE DOCUMENT ef20074977_8k_htm.xml XML 4225 Mailing Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 Business Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 (650) 391-9740 BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings) EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-38959 | Film No.: 261026012 SIC: 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)